PTK2 and pancreatic neoplasm: To date, clinical assessment of single-agent FAK inhibition has resulted in disease stabilisation in solid tumours including colorectal, ovarian and pancreatic cancer [42,50] with the potential of FAK inhibitors to enhance treatment efficacy in combination therapies warranting further investigation.